RxDoctor Payments Data

Henry Prillaman, MD

Urology · Newport News, VANPI 1740268853

Payments from drug & device makers

$1,690in general payments, 2019–2025

Across 76 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$570
  • Astellas Pharma US Inc$366
  • Antares Pharma, Inc.$158
  • Boston Scientific$80
  • AbbVie$72
  • Medtronic$69
  • plus $375 from 15 others

What the payments were for

  • Food & beverage$1,67399%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,690 in reported general payments places this provider in the 40th percentile of 300 urology providers in Virginia.

See all urology providers in Virginia

Medicare billing

Part B allowed, 2024
$73,049
Medicare patients
489
Services billed
773

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron55$47,195
GemtesaVibegron12$7,754
Tamsulosin Hcl334$4,464
Testosterone14$3,672
Finasteride159$2,496
Oxybutynin Chloride ErOxybutynin Chloride68$1,463
Alfuzosin Hcl ErAlfuzosin Hcl60$812
NitrofurantoinNitrofurantoin Macrocrystal25$807
Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl12$782
Testosterone Cypionate14$366
Cephalexin43$312
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip11$183
Dutasteride13$168
Ciprofloxacin Hcl25$139
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$80

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$366$47,19555 claims
Sumitomo Pharma America, Inc.Gemtesa$32$7,75412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 300 urology providers in Virginia.

Other urology in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →